About Regenxbio
Regenxbio is a company based in Rockville (United States) founded in 2008. Regenxbio has raised $108.39 million across 16 funding rounds from investors including NIH, HHS and Janus Henderson Investors. The company has 353 employees. Regenxbio offers products and services including ABBV-RGX-314, RGX-202, and RGX-121. Regenxbio operates in a competitive market with competitors including Insitro, BridgeBio, Moderna, ATAI and Forge Biologics, among others.
- Headquarter Rockville, United States
- Employees 353
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website regenxbio.com
- Social LinkedIn X
- Legal Name Regenxbio Inc.
- Annual Revenue$170.44 M (USD)104.54as on Dec 31, 2025
- Net Profit-$193.88 M (USD)14.63as on Dec 31, 2025
- EBITDA-$145.58 M (USD)32.3as on Dec 31, 2025
- Total Equity Funding$108.39M (USD)
in 16 rounds
- Latest Funding Round$255.95K (USD), Grant
Sep 2020
- InvestorsNIH
& 15 more
- Employee Count353
Products & Services of Regenxbio
Regenxbio offers a comprehensive portfolio of products and services, including ABBV-RGX-314, RGX-202, and RGX-121.
Treatment for retinal diseases using AAV vectors.
Therapy for Duchenne muscular dystrophy.
Treatment for Hunter Syndrome.
Funding Insights of Regenxbio
Regenxbio has successfully raised a total of $108.39M across 16 strategic funding rounds. The most recent funding activity was a Grant round of $255.95 thousand completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $108.39M
- Total Rounds 16
- Last Round Grant — $255,947
- First Round $263,277
(Jun 2010)
- Investors Count 16
Latest 10 of 16 funding rounds of Regenxbio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $255,947 | Grant | – | – | |
| Sep 2019 | $220,000 | Grant | – | – | |
| May 2015 | $70.5M | Series D | – | Brookside Capital, Venrock | |
| Jan 2015 | $30M | Series C | – | Brookside Capital, Venrock | |
| Jan 2015 | $261,327 | Grant | – | – | |
| Nov 2013 | $7.89M | Series A | – | – | – |
| Jun 2013 | – | Series A | – | – | |
| May 2013 | $211,009 | Grant | – | – | |
| Mar 2013 | $7.7M | Grant | – | – | – |
| Feb 2013 | $261,327 | Grant | – | – |
16 investors in total: 16 institutional.
Investors in Regenxbio
Regenxbio has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage investment firm invests in healthcare and life sciences companies | – | foresitecapital.com | New York, United States | |
Investment management in biotech, technology, energy, shipping, financials, and litigation sectors. | 2003 | qvt.com | - | |
Venture capital firm focused on multiple sectors | – | brooksidecapital.com | San Francisco, United States | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Venture capital and private equity firm | – | vivocapital.com | Palo Alto, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States |
Investor details for Regenxbio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Regenxbio
105 people are tracked at Regenxbio (57 in leadership, 9 in board & advisors, 39 in team); the tracked headcount is 353.
| Name | Role | Group |
|---|---|---|
Kenneth Mills | CEO & President | Leadership |
Christopher Drummond | Associate Director Of Toxicology | Leadership |
Melissa Alvidrez | Director, Clinical Operations | Leadership |
Shiva G. Fritsch | Chief Communications & People Officer | Leadership |
Patrick J. Christmas II | Chief Legal Officer | Leadership |
Mark Murphy | Senior Vice President, Finance | Leadership |
Brian Chow | Director, Financial Planning & Analysis | Leadership |
Alina Vanessa Jimenez | Associate Director | Leadership |
Joseph Hagood | Director Clinical Operations | Leadership |
Ken Mills | President & CEO | Leadership |
Rushi Shah | Senior Director Medical Affairs | Leadership |
Nina Hunter | Vice President, Regulatory And Corporate Strategy | Leadership |
Janet Yu | Associate Director, Regulatory Affairs | Leadership |
Steve Pakola | Chief Medical Officer | Leadership |
Olivier Danos | Chief Scientific Officer | Leadership |
Darcy Weyant | Director, Clinical Supply | Leadership |
Craig Malzahn | Chief Technology Officer | Leadership |
Brandon Butler | Associate Director, Clinical Trial Systems | Leadership |
Dana Fisher Cormack | Senior Director Corporate Communications | Leadership |
Paul Oyefesobi | Associate Director, Pricing And Market Access | Leadership |
85 more people are available in the full profile.
Complete people profiles for Regenxbio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Regenxbio
Regenxbio is a publicly listed company on the NASDAQ with ticker symbol RGNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Sep 2015
- Listed onNASDAQ: RGNX
- Listed entityREGENXBIO Inc.
- Exchange sectorHealth technology
- ISINUS75901B1070
- Share price$8.07 (-0.25% on the day) · 2026-10-09
- Market capitalisation$532.7M
- EPS (diluted, trailing year)$-3.79
- Volume (last session)859,286
Financials of Regenxbio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $170.4M | -$193.9M | -$145.6M |
| 2024 | $83.3M | -$227.1M | -$215.0M |
| 2023 | $90.2M | -$263.5M | -$250.8M |
| 2022 | $112.7M | -$280.3M | -$250.0M |
| 2021 | $470.4M | $127.8M | $169.5M |
Detailed financial statements for Regenxbio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Regenxbio
4 dated milestones of Regenxbio across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Regenxbio is founded.
- Funding First funding round of $263K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $256K.
Competitors of Regenxbio
Regenxbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, Moderna, ATAI and Forge Biologics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. |
Detailed competitors of Regenxbio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Regenxbio
The website of Regenxbio (regenxbio.com) receives about 19.6K visits a month and ranks #1,503,859 among all websites worldwide, #1,983 in Biotechnology and Pharmaceuticals.
- Monthly visits19.6K
▲ 15.2% vs previous month
- Unique visitors8.1K
per month
- Global rank#1,503,859
among all websites
- Category rank#1,983
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.8
- Average visit34 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with Regenxbio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
abbvieclinicaltrials.com | abbvieclinicaltrials.com | 100% | – | #2,029,589 | – |
| lysogene.com | 93% | – | – | View details | |
news.abbvie.com | news.abbvie.com | 92% | – | #600,208 | – |
| portola.com | 86% | – | – | View details | |
| ptcbio.com | 86% | 24.4K | #1,154,739 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Regenxbio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Regenxbio
Complete news archive for Regenxbio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Regenxbio
10 companies that operate in the same segment as Regenxbio (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Regenxbio
Regenxbio was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Regenxbio is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Kenneth Mills is the current CEO of Regenxbio.
Regenxbio is a funded company, having raised a total of $108.39M across 16 funding rounds to date. The company's 1st funding round was a Grant of $261.33K, raised on Jun 2010.
Regenxbio has 353 employees.
Annual revenue of Regenxbio is $170.44M as on Dec 31, 2025.
Regenxbio was founded in 2008 and is headquartered in Rockville, United States. Gene therapies based on adeno-associated virus (AAV) vectors are developed by the company through its proprietary NAV Technology Platform. Programs target rare genetic conditions such as homozygous familial hypercholesterolemia (HoFH) and Mucopolysaccharidosis Type I (MPS I), with additional candidates in development for liver, neurological, and retinal diseases.
Regenxbio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Regenxbio offers ABBV-RGX-314, RGX-202, and RGX-121.
Yes, Regenxbio is publicly traded on NASDAQ under the ticker symbol RGNX.
Regenxbio has 16 investors. Key investors include NIH, HHS, Janus Henderson Investors, RTW Investments, and Perceptive Advisors.
Regenxbio operates through Regenxbio Inc.